Russian Journal of Biotherapy

Российский биотерапевтический журнал

1726-97841726-9792

Publishing House ABV Press

813

10.17650/1726-9784-2016-15-2-82-89

REVIEWS

ОБЗОРЫ ЛИТЕРАТУРЫ

Melanocytic skin neoplasms in children

Меланоцитарные новообразования кожи у детей

Volgareva

G. M.

Волгарева

Галина Михайловна

Russian Federation

galina.volgareva@yandex.ru

Lebedeva

A. V.

Лебедева

А. В.

Russian Federation

N.N. Blokhin Russian Cancer Research Center, Ministry of Health of RussiaФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России

30062016

152828910042018

https://bioterapevt.abvpress.ru/jour/article/view/813

Literature data on peculiarities of melanocytic skin neoplasms in children and adolescents have been analyzed in order to evaluate topicality of research into the diagnostic markers complex for skin melanoma in these patients as well as, if the conclusion is in the affirmative, to characterize the would-be complex of such markers. Skin melanoma in children and adolescents is a heterogeneous tumor group which when compared with adult skin melanoma possesses both some features of similarity and a number of essential distinctions. Differential diagnostics between pigment nevus and melanoma remains rather intricate for professionals. These difficulties might be minimized by application of molecular markers. As a possible approach to differential diagnostics between nevi and malignant skin melanoma in children it seems worthwhile to try the following steps: to reveal INK4a/ARF locus lesions and to detect the protein p16^INK4a by immunohistochemistry; to check for amplifications in 11q13 chromosomal region as well as to carry out immunohistochemical detection of cyclin D1 (protein CCND1) in cellular nuclei; to reveal HLA class I antigens on surfaces of pigment cell neoplasms in immunohistochemical test.

меланоцитневусмеланома кожимаркерmelanocytenevusskin melanomamarker1.Мень Т.Х., Дорошенко М.Б., Алиев М.Д. Злокачественная меланома кожи у детей и подростков в России: популяционное эпидемиологическое исследование. Саркомы костей, мягких тканей и опухоли кожи 2011;(2):55-60.2.Jen M., Murphy M., Grant-Kels J.M. Childhood melanoma. Clin Dermatol 2009;27(6):529-36. doi: 10.1016/j.clinder-matol.2008.09.011. PMID:19880040.3.Харкевич Г.Ю., Казубская Т.П., Агапова Р.К. и др. Клинико-генетические аспекты меланомы кожи. II. Взаимосвязь и патогенетическая общность меланомы кожи с диспластическими невусами. Генетика 1995;31(11):1562-5.4.Гребенникова О.П., Прилепо В.Н. В кн.: Онкология для практикующих врачей (ред. С.С. Чистяков). М.: Авторская Академия, 2009. 548-563.5.Miller A.J., Mihm M.C. Jr. Melanoma. N Engl J Med 2006;355(1):51 -65. PMID:16822996.6.Bastian B.C. The molecular pathology of melanoma: an integrated taxonomy of me-lanocytic neoplasia. Annu Rev Pathol 2014;9:239-71. doi: 10.1146/an-nurev-pathol-012513-104658. PMID:24460190.7.Brenn Th. Pitfalls in the evaluation of me-lanocytic lesions. Histopathology 2012;60(5):690-705. doi: 10.1111/j.1365-2559.2011.04042.x. Epub 2011 Dec 16. PMID:22176022.8.Поляков В.Г., Шишков Р.В. Клинические рекомендации по диагностике и лечению меланомы у детей и подростков. Проект. Общероссийский союз общественных объединений. Ассоциация онкологов России. М., 2014.9.Hamm H., Hoger P.H. Skin tumors in childhood. Dtsch Arztebl Int 2011;108(20):347-53. doi: 10.3238/arz-tebl.2011.0347. Epub 2011 May 20. PMID:21655460.10.Kirkwood J.M., Jukic D., Averbook B.J., Sender LS. Melanoma in pediatric, adolescent and young adult patients. Semin Oncol 2009;36(5):419-31. doi: 10.1053/j.seminon-col.2009.07.001. PMID:19835737.11.Averbook B.J., Lee S.J., Delman K.L. et al. Pediatric melanoma: analysis of an in ternational registry. Cancer 2013;119(22):4012-9. doi: 10.1002/ cncr.28289. Epub 2013 Sep 10. PMID:24022819.12.Мень Т.Х., Рыков М.Ю., Поляков В.Г. Злокачественные новообразования у детей в России: основные показатели и тенденции. Российский онкологический журнал 2015;20(2):43-7.13.Paradela S., Fonseca E., Pita-Fernandez S. et al. Prognostic factors for melanoma in children and adolescents. Cancer 2010;116(18):4334-44. doi: 10.1002/ cncr.25222. PMID:20549825.14.Дурнов Л.А., Паршикова С.М., Чернова Н.В. Меланома кожи у детей. Педиатрия 1983;10:58-61.15.Чернова Н.В., Дурнов Л.А., Лебедев В.И. и др. Меланома кожи у детей. Педиатрия 1999;(3):65-7.16.Малишевская Н.П., Соколова А.В. Современные методы неинвазивной диагностики меланомы кожи. Вестник дерматологии и венерологии 2014;(4):46-53.17.Wechsler J., Bastuji-Garin S., Spatz A. et al. Reliability of histopathologic diagnosis of malignant melanoma in children. Arch Dermatol 2002;138(5):625-8. PMID:12020223.18.Cesinaro A.M., Schirosi L., Bettelli S. et al. Alterations of 9p21 analysed by FISH and MLPA distinguish atypical melanocytic tumours from conventional Spitz’s nevi but do not predict their biological behavior. Histopathology 2010;57(4):515-27. doi: 10.1111/j.1365-2559.2010.03653.x. Epub 2010 Sep 22. PMID:20860655.19.Dummer R., Kerl K., Mihic D., Kamarachev J. Differential diagnosis of me-lanocytic lesions and molecular biology. Arch Dermatol 2011;147(2):232-3. doi: 10.1001/ archdermatol.2010.438. PMID:21339451.20.Mones J.M., Ackerman A.B. Melanoma in prerubescent children: review comprehensively, critique historically, criteria diagnosti-cally, and course biologically. Am J Dermato-pathol 2003;25(3):223-38. PMID:12775985.21.Ferrari A., Bono A., Baldi M. et al. Does melanoma behave differently in younger children than in adults? A retrospective study of 33 cases of childhood melanoma from a single institution. Pediatrics 2005;115(3):649-54. PMID:15741367.22.Lu C., Zhang J., Nagahawatte P. et al. The genomic landscape of childhood and adolescent melanoma. J Invest Dermatol 2015;135(3):816-23. doi: 10.1038/ jid.2014.425. Epub 2014 Sep 30. PMID:25268584.23.Волгарева Г.М., Байкова В.Н., Лебедева А.В., Алиев М.Д. Изучение молекулярных особенностей пигментных новообразований кожи как задача детской онкологии. Обзор литературы. Детская онкология 2012;(4):3-13.24.Gould Rothberg B.E., Rimm D.L. Biomarkers: the useful and the not so useful - an assessment of molecular prognostic markers for cutaneous melanoma. J Invest Dermatol 2010;130(8):1971-87. doi: 10.1038/ jid.2010.149. Epub 2010 Jun 17. PMID:2055347.25.Bleyer A., Barr R., Hayes-Lattin B. et al. The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer 2008;8(4):288-98. doi: 10.1038/nrc2349. PMID:18354417.26.Livestro D.P., Kaine E.M., Michaelson J.S. et al. Melanoma in the young: differences and similarities with adult melanoma. A case-matched controlled analysis. Cancer 2007;110(3):614-24. PMID:17577228.27.Yancovitz M., Litterman A., Yoon J. et al. Intra- and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma. PLoS One 2012;7(1):e29336. doi: 10.1371/journal. pone.0029336. Epub 2012 Jan 3. PMID:22235286.28.Somasundaram R., Villanueva J., Herlyn M. Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations. Adv Pharmacol 2012;65:335-59. doi: 10.1016/B978-0-12-397927-8.00011-7. PMID:22959031.29.Clarke M.F., Dick J.E., Dirks P.B. et al. Cancer stem cells - perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 2006;66(19):9339-44. Epub 2006 Sep 21. PMID:16990346.30.Quintana E., Shackleton M., Sabel M.S. et al. Efficient tumor formation by single human melanoma cells. Nature 2008;456(7222):593-8. doi: 10.1038/na-ture07567. PMID:19052619.31.Lang D., Mascarenhas J.B., Shea C.R. Melanocytes, melanocyte stem cells and melanoma stem cells. Clin Dermatol 2013;31(2):166-78. doi: 10.1016/j.clinder-matol.2012.08.014. PMID:23438380.32.Schlaak M., Schmidt P., Bangard C. et al. Regression of metastatic melanoma by targeting cancer stem cells. Oncotarget 2012;3(1):22-30. PMID:22289880.33.Kong Y., Kumar S.M., Xu X. Molecular pathogenesis of sporadic melanoma and melanoma-initiating cells. Arch Pathol Lab Med 2010;134(12):1740-9. doi: 10.1043/2009-0418-RAR.1. PMID:21128770.34.Sharpless N.E., DePinho R.A. The INK4A/ARF locus and its two gene products. Curr Opin Genet Dev 1999;9(1):22-30. PMID:10072356.35.Sharpless N.E., Kannan K., Xu J. et al. Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo. Oncogene 2003;22(32):5055-9. PMID:12902988.36.Krishnamurthy J., Ramsey M.R., Ligon K.L. et al. p16INK4a induces an age-dependent decline in islet regenerative potential. Nature 2006;443(7110):453-7. Epub 2006 Sep 6. PMID:16957737.37.Molofsky A.V., Slutsky S.G., Joseph N.M. et al. Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. Nature 2006;443(7110):448-52. Epub 2006 Sep 6. PMID:16957738.38.Jenkins N.J., Liu T., Cassidy P. et al. The p16INK4a tumor suppressor regulates cellular oxidative stress. Oncogene 2011;30(3):265-74. doi: 10.1038/ onc.2010.419. Epub 2010 Sep 13. PMID:20838381.39.Gray-Schopfer V.C., Cheong S.C., Chong H. et al. Cellular senescence in naevi and immortalization in melanoma: a role for p16? Br J Cancer 2006;95(4):496-505. Epub 2006 Aug 1. PMID:16880792.40.Lamb J., Ramaswamy S., Ford H.L. et al. A mechanism of cyclin D1 action encoded in the pattern of gene expression in human cancer. Cell 2003;114(3):323-34. PMID:12914697.41.Bastian B.C., LeBoit P.E., Hamm H. et al. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 1998;58(10):2170-5. PMID:9605762.42.Gerami P., Jewell S.S., Pouryazdanparast P. et al. Copy number gains in 11q13 and 8q24 are highly linked to prognosis in cutaneous malignant melanoma. J Mol Diagn 2011;13(3):352-8. doi: 10.1016/j. jmoldx.2011.01.011. PMID:21497295.43.Oba J., Nakahara T., Abe T. et al. Expression of c-Kit, p-ERK and cyclin D1 in malig nant melanoma: an immunohistochemical study and analysis of prognostic value. J Dermatol Sci 2011;62(2):116-23. doi: 10.1016/j.jdermsci.2011.02.011. Epub 2011 Mar 5. PMID:21454057.44.Vizkeleti L., Ecsedi S., Rakosy Z. et al. The role of CCND1 alterations during the progression of cutaneous malignant melanoma. Tumour Biol 2012;33(6):2189-99. doi: 10.1007/s13277-012-0480-6. Epub 2012 Sep 23. PMID:23001925.45.Campoli M., Ferrone S. HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition. Semin Immunopathol 2011;33(4):321-34. doi: 10.1007/s00281-011-0270-z. Epub 2011 Apr 28. PMID:21523560.46.Carretero R., Wang E., Rodriguez A.I. et al. Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int J Cancer 2012;131(2):387-95. doi: 10.1002/ ijc.26471. Epub 2011 Nov 9. PMID:21964766.47.Ruiter D.J., Bhan A.K., Harrist T.J. et al. Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations and malignant melanoma. J Immunol 1982;129(6):2808-15. PMID:6183345.